Farther Finance Advisors’s Integra LifeSciences IART Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$34.6K Buy
1,914
+1,199
+168% +$16.8K ﹤0.01% 3548
2026
Q1
$6.84K Sell
715
-100
-12% -$1.1K ﹤0.01% 4331
2025
Q4
$10.1K Buy
815
+294
+56% +$3.91K ﹤0.01% 3900
2025
Q3
$7.47K Buy
521
+121
+30% +$1.66K ﹤0.01% 3575
2025
Q2
$4.91K Sell
400
-40
-9% -$581 ﹤0.01% 3364
2025
Q1
$9.51K Buy
440
+400
+1,000% +$9.41K ﹤0.01% 2761
2024
Q4
$907 Sell
40
-15
-27% -$327 ﹤0.01% 3283
2024
Q3
$999 Sell
55
-7,509
-99% -$174K ﹤0.01% 3245
2024
Q2
$219K Buy
7,564
+7,499
+11,537% +$222K 0.01% 806
2024
Q1
$2.26K Sell
65
-49
-43% -$1.96K ﹤0.01% 2436
2023
Q4
$4.96K Buy
+114
New +$4.49K ﹤0.01% 1969
2023
Q3
Sell
-5
Closed -$206 2650
2023
Q2
$206 Sell
5
-12
-71% -$578 ﹤0.01% 2364
2023
Q1
$976 Buy
17
+12
+240% +$676 ﹤0.01% 1852
2022
Q4
$280 Buy
+5
New +$254 ﹤0.01% 1958

Other funds holding IART

Farther Finance Advisors's IART Position: Q2 2026 in Review

Farther Finance Advisors increased its Integra LifeSciences (IART) stake by 168% in Q2 2026, buying an estimated $16.8K and bringing the position to 1,914 shares worth $34.6K. The position accounts for ﹤0.01% of the portfolio, ranked #3548.

Farther Finance Advisors first reported a position in IART in Q4 2022 and has held it in 14 quarters since. The position peaked at $219K in Q2 2024. 16 funds tracked by Wall St. Rank hold IART as of Q2 2026.

  • Farther Finance Advisors held 1,914 shares of Integra LifeSciences worth $34.6K as of Q2 2026.
  • Farther Finance Advisors bought 1,199 Integra LifeSciences shares in Q2 2026, an estimated $16.8K.
  • Integra LifeSciences made up ﹤0.01% of Farther Finance Advisors's portfolio in Q2 2026, its #3548 holding.
  • Farther Finance Advisors first reported a position in Integra LifeSciences in Q4 2022 and has held it in 14 quarters since.
  • Farther Finance Advisors's Integra LifeSciences position peaked at $219K in Q2 2024.
  • 16 funds tracked by Wall St. Rank held Integra LifeSciences as of Q2 2026.

Based on Farther Finance Advisors's 13F filing for Q2 2026, filed 17 Jul 2026.